SynthesisNaunyn-Schmiedeberg's archives of pharmacology2026
Methodological quality of network meta-analyses of Chinese herbal medicine could be improved: an evidence mapping.
Synthesis in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multidimensional evaluation of four chaihu-shugan-san simulated decoction for use as placebo controls: a comparative study.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Network meta-analyses (NMAs) are essential for comparing multiple Chinese herbal medicine (CHM) interventions, but their methodological rigor requires evaluation. We systematically searched five databases for CHM NMAs published from inception to June 2025. Studies were included if they were English-language, SCI/SSCI-indexed NMAs evaluating at least one pharmacopoeia-listed CHM. Conference abstracts, editorials, expert opinions, conference proceedings, case reports, and Meta-analyses were excluded. Two reviewers independently screened studies, extracted data, and appraised methodological quality using AMSTAR 2. Factors associated with quality (dichotomized as high/moderate vs. low/critically low) were examined using logistic regression. Of 1,016 identified records, 212 NMAs were included, encompassing 13,575 primary studies and 1,302,518 participants. Methodological quality was generally low: 1.42% were high, 5.19% moderate, 61.32% low, and 32.08% critically low. Common shortcomings involved literature search comprehensiveness, listing of excluded studies, reporting of funding sources for included trials, and assessment of risk of bias impact. In multivariable analysis, a larger number of authors (OR = 1.177, 95% CI: 1.014-1.366, p = 0.032) was associated with higher quality. An association was also observed for non-China corresponding author country (OR = 7.914, 95% CI: 1.360-46.065, p = 0.021), although the wide confidence interval warrants cautious interpretation. The assessment was based on AMSTAR 2, which is not NMA-specific. Restriction to SCI/SSCI journals may have excluded lower-quality studies. This work was supported by grants from the National Natural Science Foundation of China (82,305,209, 82,505,508) and other local funds. This systematic review was not preregistered. The methodological quality of published CHM NMAs is predominantly low. Enhancing team size and collaboration, alongside strict adherence to core methodological standards, is crucial for improving the reliability and utility of future evidence syntheses in this field.
Indexed as
Identifiers
41606226What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.